Positive News Sentiment NASDAQ:INZY Inozyme Pharma - INZY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.04 +0.28 (+10.14%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.76▼$3.1850-Day Range$1.71▼$3.2552-Week Range$0.99▼$6.25Volume837,730 shsAverage Volume1.60 million shsMarket Capitalization$122.79 millionP/E RatioN/ADividend YieldN/APrice Target$17.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Inozyme Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside483.9% Upside$17.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.84) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector583rd out of 983 stocksPharmaceutical Preparations Industry280th out of 478 stocks 3.4 Analyst's Opinion Consensus RatingInozyme Pharma has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.75, Inozyme Pharma has a forecasted upside of 483.9% from its current price of $3.04.Amount of Analyst CoverageInozyme Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for INZY. Previous Next 0.0 Dividend Strength Dividend YieldInozyme Pharma does not currently pay a dividend.Dividend GrowthInozyme Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INZY. Previous Next 2.7 News and Social Media Coverage News SentimentInozyme Pharma has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inozyme Pharma this week, compared to 1 article on an average week.Search InterestOnly 25 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inozyme Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.72% of the stock of Inozyme Pharma is held by insiders.Percentage Held by Institutions76.35% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.84) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inozyme Pharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inozyme Pharma is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInozyme Pharma has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inozyme Pharma (NASDAQ:INZY) StockInozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Stock News HeadlinesMarch 16, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Inozyme (INZY)March 1, 2023 | finance.yahoo.comInozyme Pharma to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 22, 2023 | Upexi, Inc (Ad)Could This Be The Biggest Stock Of 2023?This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!February 24, 2023 | finance.yahoo.comWhy Inozyme Pharma (INZY) Shares Are Trading Higher TodayFebruary 22, 2023 | benzinga.comShort Volatility Alert: Inozyme Pharma IncFebruary 16, 2023 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Inozyme Pharma (INZY)February 16, 2023 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701February 16, 2023 | marketwatch.comInozyme Pharma Shares Rise 38% After Positive Trial Data for INZ-701March 22, 2023 | Upexi, Inc (Ad)Could This Be The Biggest Stock Of 2023?This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!February 16, 2023 | msn.comInozyme adds 36% on Phase 1/2 data for lead asset and cash runwayFebruary 16, 2023 | msn.comINZY Soars on Promising INZ-701 DataFebruary 16, 2023 | msn.comInozyme Pharma up 31% on phase 1/2 data for blood vessel disorderFebruary 16, 2023 | finance.yahoo.comInozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701February 6, 2023 | finance.yahoo.comInozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023February 4, 2023 | finance.yahoo.comInstitutions profited after Inozyme Pharma, Inc.'s (NASDAQ:INZY) market cap rose US$19m last week butprivate equity firms profited the mostJanuary 24, 2023 | seekingalpha.comINZY Inozyme Pharma, Inc.January 9, 2023 | finance.yahoo.comInozyme Pharma Announces Investor and Analyst Event and Highlights 2022 ProgressDecember 5, 2022 | finance.yahoo.comInozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 DeficiencyDecember 1, 2022 | finance.yahoo.comInozyme Pharma to Participate at the BofA Securities Biotech SMID Cap ConferenceNovember 10, 2022 | finance.yahoo.comInozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 7, 2022 | finance.yahoo.comInozyme Pharma to Participate in Upcoming Investor ConferencesNovember 6, 2022 | finance.yahoo.comInozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$11m market cap decline means a loss of US$268k for insiders who bought this yearNovember 3, 2022 | finance.yahoo.comInozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical TrialOctober 31, 2022 | finance.yahoo.comInozyme Pharma Announces Publication of Comprehensive ENPP1 Variant DatabaseSeptember 26, 2022 | finance.yahoo.comWe're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn RateSeptember 6, 2022 | finance.yahoo.comInozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment ConferenceAugust 17, 2022 | finance.yahoo.comArtelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Company Calendar Last Earnings11/09/2021Today3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INZY CUSIPN/A CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.75 High Stock Price Forecast$23.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+483.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.20% Return on Assets-49.06% Debt Debt-to-Equity Ratio0.03 Current Ratio11.11 Quick Ratio11.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.66Miscellaneous Outstanding Shares40,390,000Free Float36,468,000Market Cap$122.79 million OptionableNot Optionable Beta0.79 Key ExecutivesMr. Axel Bolte M.B.A. (Age 50)M.Sc., Co-Founder, Pres, CEO & Director Comp: $889.66kMr. Henric Bjorn Bjarke (Age 55)Sr. VP & COO Comp: $597.68kDr. Demetrios Braddock M.D.Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverMr. Sanjay S. Subramanian M.B.A. (Age 45)M.S., CFO & Principal Accounting Officer Dr. Soojin Kim Ph.D.Sr. VP & Chief Technical Operations OfficerDr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific OfficerMr. Stefan RileyDirector of Investor RelationsMs. Gayle GirondaSr. VP & Chief People OfficerDr. David Thompson M.A.M.S., Ph.D., Chief Devel. OfficerMr. Stephen J. Di Palma M.B.A (Age 63)M.B.A., Consultant More ExecutivesKey CompetitorsRVL PharmaceuticalsNASDAQ:RVLPDURECTNASDAQ:DRRXShattuck LabsNASDAQ:STTKAlaunos TherapeuticsNASDAQ:TCRTChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsSphera Funds Management LTD.Bought 450,000 shares on 2/15/2023Ownership: 4.023%Millennium Management LLCBought 127,752 shares on 2/15/2023Ownership: 0.738%State of Wisconsin Investment BoardSold 11,100 shares on 2/15/2023Ownership: 0.093%Renaissance Technologies LLCBought 103,500 shares on 2/13/2023Ownership: 0.641%NEA Management Company LLCSold 6,690 shares on 2/10/2023Ownership: 6.035%View All Insider TransactionsView All Institutional Transactions INZY Stock - Frequently Asked Questions Should I buy or sell Inozyme Pharma stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INZY shares. View INZY analyst ratings or view top-rated stocks. What is Inozyme Pharma's stock price forecast for 2023? 4 Wall Street research analysts have issued 1 year target prices for Inozyme Pharma's stock. Their INZY share price forecasts range from $5.00 to $23.00. On average, they predict the company's stock price to reach $17.75 in the next twelve months. This suggests a possible upside of 483.9% from the stock's current price. View analysts price targets for INZY or view top-rated stocks among Wall Street analysts. How have INZY shares performed in 2023? Inozyme Pharma's stock was trading at $1.05 at the beginning of the year. Since then, INZY shares have increased by 189.5% and is now trading at $3.04. View the best growth stocks for 2023 here. How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.01. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Honeywell International (HON), Procter & Gamble (PG), Raytheon Technologies (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT). When did Inozyme Pharma IPO? (INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Inozyme Pharma's stock symbol? Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY." Who are Inozyme Pharma's major shareholders? Inozyme Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (6.04%), Sphera Funds Management LTD. (4.02%), Millennium Management LLC (0.74%), Renaissance Technologies LLC (0.64%), State of Wisconsin Investment Board (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner. View institutional ownership trends. How do I buy shares of Inozyme Pharma? Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inozyme Pharma's stock price today? One share of INZY stock can currently be purchased for approximately $3.04. How much money does Inozyme Pharma make? Inozyme Pharma (NASDAQ:INZY) has a market capitalization of $122.79 million. The company earns $-56,620,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. How can I contact Inozyme Pharma? The official website for the company is www.inozyme.com. The company can be reached via phone at 857-330-4340 or via email at ir@inozyme.com. This page (NASDAQ:INZY) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.